stoxline Quote Chart Rank Option Currency Glossary
RxSight, Inc. (RXST)
56.11  -1.78 (-3.07%)    06-17 16:00
Open: 57.91
High: 58.94
Volume: 460,418
Pre. Close: 57.89
Low: 55.4201
Market Cap: 2,187(M)
Technical analysis
2024-06-17 5:26:16 PM
Short term     
Mid term     
Targets 6-month :  71.22 1-year :  75.33
Resists First :  60.97 Second :  64.5
Pivot price 58.35
Supports First :  55.27 Second :  45.99
MAs MA(5) :  57.78 MA(20) :  59.19
MA(100) :  54.36 MA(250) :  40.3
MACD MACD :  -0.3 Signal :  0.1
%K %D K(14,3) :  33 D(3) :  36.1
RSI RSI(14): 42.9
52-week High :  66.54 Low :  20.65
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ RXST ] has closed above bottom band by 7.4%. Bollinger Bands are 39.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 58.97 - 59.36 59.36 - 59.69
Low: 54.69 - 55.06 55.06 - 55.37
Close: 55.56 - 56.17 56.17 - 56.67
Company Description

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Headline News

Thu, 13 Jun 2024
Parkman Healthcare Partners LLC Has $20.69 Million Position in RxSight, Inc. (NASDAQ:RXST) - MarketBeat

Tue, 11 Jun 2024
Lighthouse Investment Partners LLC Buys New Shares in RxSight, Inc. (NASDAQ:RXST) - MarketBeat

Mon, 10 Jun 2024
Seven Eight Capital LP Purchases New Position in RxSight, Inc. (NASDAQ:RXST) - Defense World

Wed, 05 Jun 2024
RxSight, Inc. (NASDAQ:RXST) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Thu, 30 May 2024
With 71% ownership, RxSight, Inc. (NASDAQ:RXST) boasts of strong institutional backing - Simply Wall St

Tue, 28 May 2024
What Makes RxSight, Inc. (RXST) a Strong Momentum Stock: Buy Now? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Medical - Devices
Shares Out 39 (M)
Shares Float 32 (M)
Held by Insiders 5.1 (%)
Held by Institutions 83.7 (%)
Shares Short 1,400 (K)
Shares Short P.Month 1,470 (K)
Stock Financials
EPS -1.25
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.4
Profit Margin -44.1 %
Operating Margin -36.2 %
Return on Assets (ttm) -15.5 %
Return on Equity (ttm) -28.9 %
Qtrly Rev. Growth 68.6 %
Gross Profit (p.s.) 0
Sales Per Share 2.57
EBITDA (p.s.) -1.11
Qtrly Earnings Growth 0 %
Operating Cash Flow -33 (M)
Levered Free Cash Flow -21 (M)
Stock Valuations
PE Ratio -45.25
PEG Ratio -4.2
Price to Book value 12.72
Price to Sales 21.78
Price to Cash Flow -66.46
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android